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S U M M A R Y
Background: In epidemiologic research, incidence is often estimated from data arising from an imperfect
diagnostic test performed at unequally spaced intervals over time.
Methods: We developed a likelihood-based method to estimate incidence when disease status is
measured imperfectly and assays are performed at multiple unequally spaced visits. We assumed
conditional independence, no remission, known constant levels of sensitivity and speciﬁcity, and
constant incidence rates over time. The method performance was evaluated by examining its bias,
accuracy (i.e., mean squared error (MSE)), and coverage probability in a simulation study of 4000
datasets, and then we applied the proposed method to a study of hepatitis C virus (HCV) infection in a
cohort of pregnant women in the period 1997–2006.
Results: The simulation revealed that our method has minimal bias and low MSE, as well as good
coverage probability of the resulting conﬁdence intervals. In the application to HCV study, the standard
incidence rate estimate which ignores the imperfections of the diagnostic test (number of events/
person-years), was 13.7 new HCV cases per 1000 person-years (95% conﬁdence interval 10.1, 17.4). The
adjusted incidence estimates (obtained using our proposed method) ranged from 0.4 cases per 1000
person-years (when sensitivity and speciﬁcity were assumed to both be 95%) to 13.7 cases per 1000
person-years (when sensitivity and speciﬁcity were both 100%). The magnitude of difference between
standard and adjusted estimates varied depending on speciﬁcity and sensitivity assumptions. Speciﬁcity
had the greatest impact on the magnitude of bias.
Conclusions: Scientists should be aware of the impact of misclassiﬁcation on incidence estimates.
Appropriate study design, proper selection of the diagnostic test, and adjustment for misclassiﬁcation
probabilities in the analysis is necessary to obtain the most accurate incidence estimates.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Determining disease incidence is important for measuring
disease burden, identifying risk factors, assessing prevention efforts,
and informing policy. The standard approach to estimating disease
incidence by following a cohort, calculating the number of events
and dividing it by the person-time at risk may be complicated by two
problems: (1) misclassiﬁcation of disease status if measured using
an imperfect diagnostic test, and (2) uncertainty regarding the exact
timing of disease acquisition if disease status is measured only
periodically. A number of methods have been proposed to handle
one or both of these complications,1–5 including an algebraic* Corresponding author. Tel.: +1 203 785 6232; Fax: +1 203 785 6980.
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http://dx.doi.org/10.1016/j.ijid.2012.02.017approach for adjusting cumulative incidence5 and more sophisti-
cated models such as hidden Markov models (HMM).1 In the HMM
approach adapted by Bureau et al.1 and by Smith and Vounatsou,2
disease status was modeled as hidden states of a continuous-time
process, and the diagnostic test provided imperfect measurements
of disease state. However, performance and interpretation of HMM
is highly dependent on the degree to which the assumptions of the
model are fulﬁlled.1
The aforementioned problem of incidence estimation in the
presence of an imperfect diagnostic assay for disease status is
exempliﬁed by epidemiologic studies of hepatitis C virus (HCV).
HCV infection is a chronic and silent killer estimated to affect about
200 million people worldwide6 and approximately 4 million
people in the USA alone, who have a 2.37 times higher all-cause
mortality rate ratio compared to the non-HCV-infected.7,8 Egypt is
estimated to have the highest prevalence of HCV in the world withses. Published by Elsevier Ltd. All rights reserved.
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past and 8 million people with chronic infection.9 High incidence
rates were found among children born to HCV-infected mothers,10
spouses of the HCV-infected,11 and household contacts of infected
persons living in rural villages.12,13 These previous estimates of
disease incidence might be inaccurate due to misclassiﬁcation. The
reliability (sensitivity, speciﬁcity, negative and positive predictive
values) of HCV diagnostic assays has been found to vary greatly
depending on the population studied, HCV prevalence, the
laboratory that performs the assay, and the type of assay
used.14–16 Due to differences in the laboratory methods used
and the varied reliabilities of the HCV assays, comparing inferences
from different study results are somewhat difﬁcult.14–16
In this paper, we describe a likelihood-based method to
estimate disease incidence using an imperfect diagnostic test
performed at multiple unequally spaced visits. We apply our
proposed method to a community-based study of HCV seroinci-
dence in a cohort of pregnant women. We include comparisons to
standard estimates of the incidence rate.
2. Methods
2.1. Misclassiﬁcation-adjusted incidence rate estimation
We developed a likelihood-based method to estimate incidence
when disease status is measured imperfectly and assays are
performed at multiple unequally spaced visits. We assumed: (1)
conditional independence: i.e., conditional on the true disease
status, test results obtained from the same person at different time
points are independent; (2) no remission: i.e., no probability of
spontaneously reverting from established chronic disease status to
non-disease status; (3) levels of sensitivity and speciﬁcity are
assumed to be known constants (rather than parameters to
estimate); and (4) incidence rates are constant over time. Our
proposed method for incidence estimation is an adaptation of the
HMM method described by Bureau et al.1 Our method can adjust
for differential misclassiﬁcation via the incorporation of different
misclassiﬁcation probabilities for different subjects, or at different
time points. Allowing for differential misclassiﬁcation is relevant
to HCV studies because of change in the testing method over time
and the subsequent change in the sensitivity and speciﬁcity of the
assay. We developed R code, which is available upon request, to
implement the method.
The likelihood function can be constructed based on these
assumptions (Supplementary Material). We treated disease status
as missing data, and used an expectation-maximization (EM)
algorithm to maximize the likelihood. Variances of the estimates
can be estimated in a standard way based on the observed
information matrix.17 EM involves using the standard formula for
incidence rate (incident cases/person-time) but replaces it with E
(incident cases)/E (person-time) where E(.) denotes expected
value, and the expected values are estimated based on the
probability that each person is an incident case (or not). The
expected number of incident cases can be calculated based on the
probability that each person is an incident case given the person’s
test results, and given the current estimates of incidence and
assumed values of sensitivity and speciﬁcity. For example, if a
person was measured at two time points, given the assumption of
no remission, there are three underlying ‘hidden’ possibilities: (1)
the person was uninfected at both time points, (2) the person was
uninfected at the ﬁrst time point and was infected at the second
time point (an incident case), or (3) the person was infected at both
time points (a chronically infected prevalent case). Given the
person’s test results at each time point we can calculate the
probability that the person is truly in each of those hidden states,
and then use those probabilities to calculate the value of E(incident cases). In addition, we can estimate the expected time of
follow-up for each person (including the expected time of
seroconversion given the possibility that the person was an
incident case) and use this to calculate E (person-time). These
calculations depend on the current estimate of the incidence rate,
and result in a revised estimate of incidence rate. Therefore, this
process needs to be iterated until it converges to a stable estimate
of incidence. The detailed calculation is provided in the Supple-
mentary Material. In order to obtain the 95% conﬁdence interval
(CI) we computed the approximated variance/covariance of the
adjusted incidence and prevalence estimates using a standard
likelihood approach based on the inverse of the information matrix
(Supplementary Material).
2.2. Application of the proposed method to simulated datasets
To examine the characteristics of the calculated adjusted
estimate in ﬁnite samples, given various incidence, sensitivity and
speciﬁcity assumptions, we simulated 4000 data sets (500 for each
of eight scenarios).The scenarios differed by sample size (1000 vs.
5000), true incident rate (0.01 vs. 0.10), and misclassiﬁcation rates
(95% sensitivity and speciﬁcity vs. 80% sensitivity and speciﬁcity).
Misclassiﬁed disease status was simulated from Bernoulli distri-
bution, conditioned on true disease status and sensitivity and
speciﬁcity assumptions. We assessed the performance of our
method by evaluating the proposed method bias, accuracy, and
coverage.18 For each scenario, the average adjusted estimate
IRˆaverageadj was calculated. The bias was deﬁned as the difference
between the average adjusted estimate IRˆaverageadj and the
simulated estimate IRsim. The amount of bias that exceeded
2SE(IRˆaverageadj) was considered problematic.
18 Accuracy was
assessed by the mean squared error (MSE), a measure of both
the bias and the variability. MSE was deﬁned as the average
squared deviation between estimate and truth, i.e., (IRˆadj  IRsim)2/
number of simulations. The lower the MSE the better the
performance of the method.18 To further evaluate our method
we calculated coverage probability of the resulting conﬁdence
intervals, deﬁned as the probability that the conﬁdence interval
contains the underlying true incidence parameter IRsim. A
probability coverage would be deemed reasonable if the coverage
falls within approximately two SEs of the nominal coverage
probability (p), where SE(p) = H(p(1  p)/number of simula-
tions).19 Therefore, for a 95% conﬁdence interval based on 500
independent simulations, a coverage probability between 93.05%
and 96.95% was acceptable.
2.3. Application of the proposed method to the HCV incidence study
We applied our method to a longitudinal prospective cohort
study of HCV incidence in three rural villages in Menouﬁa
Governorate in the Nile Delta in Egypt. The study enrolled 3410
pregnant women attending community health centers for prenatal
care who consented to participate. All women were ﬁrst seen
during their second or third trimester of pregnancy and asked to
return at 2 months postpartum and yearly thereafter until their
child was 5 years old. Information was gathered regarding socio-
demographic characteristics, as well as their risk factors for
acquiring HCV infection, and HCV antibodies (anti-HCV) status was
assessed at each visit.
The standard (naı¨ve) incidence estimate, IRˆnaı¨ve, of HCV among
pregnant women was calculated by dividing the number of new
apparent HCV cases (determined by the imperfect assay) over the
total person-time at risk. Thus, IRˆnaı¨ve is the maximum likelihood
estimator when the number of disease cases follows a Poisson
distribution. For women seroconverters, we used the midpoint of
the interval between laboratory assays as time of seroconversion
Table 1
Results and performance of the method in a simulation study of 4000 studies with different rates, sensitivity, speciﬁcity and sample size scenarios
Simulated
incidence rate
Sensitivity
and speciﬁcity
Sample size – 1000 Sample size – 5000
Mean estimated
incidence rate
Bias MSE CI coverage Mean estimated
incidence rate
Bias MSE CI coverage
0.01 95% and 95% 0.0101 9.64E05 2.30E06 95.8 0.0101 6.94E05 2.27E06 96.6
80% and 80% 0.0111 1.06E03 1.12E05 96.4 0.0109 9.37E04 2.75E06 93.2
0.1 95% and 95% 0.1005 5.43E04 2.71E05 95.0 0.1001 1.25E04 5.21E06 96.6
80% and 80% 0.1010 9.79E04 7.19E05 96.0 0.1012 1.23E03 1.70E05 93.2
MSE, mean squared error; CI, conﬁdence interval.
Table 2
Sensitivity analysis of the impact of various misclassiﬁcation assumptions on
adjusted incidence rate estimates
Sensitivity Speciﬁcity Adjusted incidencea Differenceb Ratioc
100% 100% 13.7 0 1
100% 99.8% 10.2 3.5 1.35
100% 99% 6.2 7.5 2.20
100% 98% 4.6 9.1 2.97
100% 97% 3.8 9.9 3.58
100% 96% 3.2 10.5 4.27
100% 95% 2.7 11.0 5.09
99% 100% 12.0 1.7 1.14
99% 99.8% 8.7 5.0 1.57
99% 99% 5.0 8.7 2.74
99% 98% 3.4 10.3 4.02
99% 97% 2.6 11.1 5.32
99% 96% 1.9 11.8 7.07
99% 95% 1.3 12.4 10.24
98% 100% 11.2 2.5 1.23
98% 99.8% 8.0 5.7 1.70
98% 99% 4.5 9.2 3.08
98% 98% 3.0 10.7 4.53
98% 97% 2.3 11.4 6.02
98% 96% 1.6 12.1 8.46
98% 95% 1.0 12.7 13.40
97% 100% 10.6 3.1 1.30
97% 99.8% 7.7 6.0 1.78
97% 99% 4.2 9.5 3.26
97% 98% 2.8 10.9 4.84
97% 97% 2.1 11.6 6.56
97% 96% 1.4 12.3 9.61
97% 95% 0.8 12.9 16.94
96% 100% 10.1 3.6 1.35
96% 99.8% 7.4 6.3 1.85
96% 99% 4.0 9.7 3.41
96% 98% 2.6 11.1 5.22
96% 97% 1.9 11.8 7.22
96% 96% 1.2 12.5 11.11
96% 95% 0.6 13.1 22.98
95% 100% 9.6 4.1 1.42
95% 99.8% 7.2 6.5 1.91
95% 99% 3.8 9.9 3.57
95% 98% 2.5 11.2 5.57
95% 97% 1.7 12.0 7.90
95% 96% 1.0 12.7 13.15
95% 95% 0.4 13.3 33.03
a Number of cases per 1000 person-years.
b Difference = naı¨ve unadjusted incidence (i.e., 13.7 cases per 1000 person-years)
 adjusted incidence.
c Ratio = naı¨ve unadjusted incidence/adjusted incidence.
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HCV among pregnant women, IRˆadj, was calculated as described
above, using a range of different values of sensitivity and
speciﬁcity.
3. Results
3.1. Simulation study
Table 1 presents the results of the simulation study. Bias
estimates were within acceptable range, such that none of the bias
estimates exceeded two times the SE (IRˆaverageadj). For a simulated
rate of 0.01, the bias ranged from 6.94E05 to 1.06E03 (from
approximately 1% to 10% of the true incidence). The least bias was
observed in simulations of larger sample size, and with best
sensitivity and speciﬁcity assumption. The highest bias was for the
simulation with the smaller sample size and the worst sensitivity
and speciﬁcity assumption. For a higher simulated rate of 0.1, the
bias was less than 1.2% of the true incidence for all scenarios, and
was the least for bigger sample size and the best sensitivity and
speciﬁcity assumption. MSE ranged from 2.30E06 to 7.19E05
for the simulation scenarios of sample size 1000 and 2.27E06 to
1.70E05 for the simulation scenarios of sample size 5000. In
particular, lower MSE was observed for simulations with larger
sample sizes and with better sensitivity and speciﬁcity. Coverage
probabilities ranged from 95.0% to 96.4% for the simulation
scenarios of sample size 1000 and 93.2% to 96.6% for the simulation
scenarios of sample size 5000. In general, coverage probabilities
increased with larger sample size and with better sensitivity and
speciﬁcity. However, when there was less variability in the
calculated estimate, the coverage probability was lower for larger
sample size.
3.2. Standard (naı¨ve) HCV seroincidence rate estimation
Among 2801 mothers at risk, 55 became anti-HCV positive after
4004.3 person-years of follow-up. Thus the standard incidence rate
estimate; IRˆnaı¨ve, was 13.7 new HCV cases per 1000 person-years
(95% CI 10.1, 17.4)
3.3. Misclassiﬁcation-adjusted incidence analysis: a sensitivity
analysis approach
To perform a sensitivity analysis, we calculated incidence
assuming that both assay sensitivity and speciﬁcity ranged from
0.95 to 1.0.20We ran the computer algorithm using different sets of
initial values and the estimates remained the same.
When sensitivity and speciﬁcity were both assumed to be 100%,
then the proposed estimator IRˆadj is almost identical to IRˆnaı¨ve,
because the assumption is tantamount to assuming that there is no
misclassiﬁcation. The only difference is the fact that the adjusted
estimate does not assume that seroconversion occurs at the
midpoint of an interval, but is based on an estimate of the expectedtime of seroconversion. This difference has little effect when
incidence is low.
However, as illustrated in Table 2, minimal declines in
speciﬁcity and sensitivity caused sizeable change in the adjusted
incidence estimate; for example, when sensitivity and speciﬁcity
were both assumed to equal 99% at all time points, IRˆadj was 5.0 per
1000 person-years (95% CI 2.2, 7.8), which was 36% of IRˆnaı¨ve, with a
ratio (IRˆ
naı¨ve=IRˆadj
) of 2.7.
Similarly, given reasonably good sensitivity (95%) and speciﬁc-
ity (95%), IRˆadj was 0.4/1000 person-years (95% CI 0.0, 2.9), which
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presumed sensitivity or speciﬁcity declined, IRˆadj decreased (Table
2) and the difference increased (Table 2). It was also noted that in
our study of HCV incidence, where the incidence was fairly low, the
magnitude of the effect of imperfect speciﬁcity on IRˆadj was much
higher than the magnitude of imperfect sensitivity. For example, in
the situation of perfect sensitivity and 99% speciﬁcity, IRˆadj was 6.2/
1000 person-years (95% CI 3.3, 9.1; ratio = 2.2), while in the
situation of perfect speciﬁcity and 99% sensitivity, IRˆadj was 12.0/
1000 person-years (95% CI 8.4, 15.6; ratio = 1.1).
Of note, IRˆadj did not meaningfully differ when the algorithm
was run using different starting values. For instance for a
sensitivity and speciﬁcity of 95%, IRˆadj ranged from 0.415 to
0.406 per 1000 person-years when the initial starting points
ranged from 0.0137 to 0.5.
4. Discussion
Reports of disease incidence can have important implications
for policy, costs, and health decisions. Thus determining incidence
with the greatest possible accuracy is crucial. Unfortunately,
incidence estimation is not only a function of case deﬁnition but
also of the reliability of the assay used.
Our results suggest that small imperfections in the assay can
have large effects on estimates of incidence. This was exempliﬁed
by our ﬁndings of a minimum HCV incidence of 0.4 cases per 1000
person-years (when sensitivity and speciﬁcity were both assumed
to be 95%) and a maximum incidence of 13.7 cases per 1000
person-years (when sensitivity and speciﬁcity were both 100%).
This big difference in estimate of disease burden might erroneously
lead to inappropriate policies and allocation of funds.
One strategy to reduce this problem is to attempt to increase
the accuracy of identiﬁcation using more expensive or frequent
assessments, or exclude some observations that were based on
less-accurate diagnostic tests. However, this may be costly, time-
consuming, and might lead to attrition, loss of some available
information, or categorizing some cases as indeterminate.21–24 Our
proposed method adjusts for misclassiﬁcation and has the
advantage of allowing inclusion of all available information, thus
reducing the need for using strict case deﬁnitions or extra
conﬁrmatory laboratory testing, and thus can be less costly.
As our results revealed, accounting for possible misclassiﬁca-
tion can sometimes result in dramatically different estimates. We
detected a higher impact of speciﬁcity compared with sensitivity
on the magnitude of bias in the HCV study. Generally, previous
reports of rare diseases have also shown that imperfect speciﬁcity
produces results with a greater magnitude of bias than does
imperfect sensitivity.3–5,25
We used the EM algorithm to estimate incidence, prevalence,
and seroconversion time parameters, an approach that was used
previously when outcomes were measured with uncertainty, or
with incomplete data.1,4,26,27 Although one of the drawbacks of the
EM algorithm is that it may reach a local maximum, not a global
maximum, this is unlikely in our study where we had only two
parameters (incidence and prevalence); thus the likelihood is
believed to be uni-modal. Furthermore, running the EM algorithm
with different initial values resulted in the same estimates. In
addition, our simulation results revealed that our method has
minimal bias and low MSE, as well as good coverage probability of
the resulting conﬁdence interval.
Although our method is useful in obtaining a misclassiﬁcation-
adjusted incidence estimate, it has some limitations. First, we
assumed the absence of spontaneous remission, i.e., once a person
has disease he/she continues to have disease or some marker of
disease. This assumption is applicable to many diseases, and is
thought to apply to HCV seroconversion. However, if remission isto be expected, our method can be extended following the methods
in Bureau et al.1 Another limitation that should be noted is the
assumption of conditional independence, which may not be true in
all situations. We also assumed that misclassiﬁcation probabilities
(i.e., sensitivity and speciﬁcity) are known constants, and we did
not provide a way of estimating them. While these probabilities are
often not known, the method we described can still be useful to
assess the degree to which estimates might be affected by different
levels of misclassiﬁcation. The method can be extended to
simultaneously estimate the misclassiﬁcation probabilities, al-
though non-identiﬁable problems and instability of estimates may
arise.
In light of our study, it is important for the researchers to realize
the impact of misclassiﬁcation on their results, and to address this
issue in the early stages of study design and during the analysis in
an attempt to minimize the resultant bias.
In conclusion, we have developed a relatively simple method to
address a frequently overlooked question: what is the best estimate
of an incidence rate given the use of diagnostic tests with imperfect
sensitivity and speciﬁcity? As our study illustrates, even in the
presence of near perfect assays, results of incidence studies can be
severely biased. To obtain the desired accurate estimates, it is of
paramount importance to choose an appropriate diagnostic assay
during the study design, and to use proper statistical methods to
adjust for misclassiﬁcation during the analysis.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2012.02.017.
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